Evaluation of epoetin supplemented with oral iron in patients with solid malignancies and chronic anemia not receiving anticancer treatment

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3495-3500

  Mystakidou, Kyriaki ^a   Kalaidopoulou, Ourania ^a   Katsouda, Emmanuela ^a   Parpa, Efi ^a   Kouskouni, Evangelia ^a   Chondros, Costas ^a   Tsiatas, Marinos L ^b   Vlahos, Lambros ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anemia; Erythropoietin; Quality of life

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; LINEAR ANALOG SCALE ASSESSMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 23344434516     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Moliterno AR and Spivak JL: Anemia of cancer. Hematol Oncol Clin North Am 10: 345-363, 1996.
2. Koeller JM: Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 18: 156-169, 1998.
3. Miller CB, Jones RJ, Piantadosi S et al: Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 522: 1689-1692, 1990.
4. Means RT Jr and Krantz SB: Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 80: 1639-1647, 1992.
5. Dainiak N, Kalkani V, Howard D et al: Mechanisms of abnormal erythropoiesis in malignancy. Cancer 57: 1101-1106, 1981.
6. Glaspy J, Bukowski R, Steinberg D et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15: 1218-1234, 1997.
7. Demetri GD, Kris M, Wade J et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 16: 3412-3425, 1998.
8. Gabrilove JL, Cleeland CS, Livingston RB et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875-2882, 2001.
9. Littlewood TJ, Bagetta E, Nortier JWR et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19: 2865-2874, 2001.
10. Platanias LC, Miller CB, Mick R et al: Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9: 2021-2026, 1991.
11. Ludwig H, Sundal E, Pecherstorfer M et al: Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 76: 2319-2329, 1995.
12. Quirt I, Robeson C, Lau CY et al: Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19: 4126-4134, 2001.
13. Macdougall IC, Tucker B, Thompson J et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996.
14. Auerbach M, Ballard H, Trout JR et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22: 1301-1307, 2004.
15. Henry DH: Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 3: 275-278, 1998.
16. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 25(suppl 7): 43-46, 1998.
17. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13-19 (suppl 2), 1997.
18. Yellen SB, Cella DF, Webster K et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Symptom Manage 13: 63-74, 1997.
19. Bokemeyer C, Aapro MS, Courdi A et al: EORTC guidelines for the use of erythropoietin proteins in anaemic patients with cancer. Eur J Cancer 40: 2201-2216, 2004.
20. Hudis CA, Van Belle S, Chang J et al: rHuEPO and treatment outcomes: the clinical experience. The Oncologist 9: 55-69, 2004.
21. Santini D, Vincenzi B, La Cesa A et al: A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study. Anticancer Res 25: 669-674, 2005.
22. Bamias A, Aravantinos G, Kalofonos C et al: Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64: 102-110, 2003.
23. Marinaccio M, Mele E, Giotta F et al: Pretreatment normalization of mild anemia with epoetin alfa: impact on the outcome in epithelial ovarian cancer patients. Proc Am Soc Clin Oncol 22: 486, 2003.
24. Niscola P, Scaramucci L, Bongarzoni V et al: Management of disease-related anemia by high doses of epoetin alfa in patients with multiple myeloma. Blood 100: 387b, 2002.